Analysts forecast that Alimera Sciences Inc (NASDAQ:ALIM) will report earnings of ($0.06) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Alimera Sciences’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.07). Alimera Sciences reported earnings of ($0.04) per share in the same quarter last year, which would indicate a negative year over year growth rate of 50%. The firm is expected to issue its next earnings results on Wednesday, November 7th.
According to Zacks, analysts expect that Alimera Sciences will report full year earnings of ($0.27) per share for the current fiscal year, with EPS estimates ranging from ($0.29) to ($0.25). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.17) to ($0.11). Zacks’ EPS averages are an average based on a survey of analysts that follow Alimera Sciences.
Alimera Sciences (NASDAQ:ALIM) last issued its earnings results on Monday, July 30th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.06). The business had revenue of $10.92 million during the quarter, compared to the consensus estimate of $10.78 million.
ALIM has been the topic of a number of recent research reports. Cowen reissued a “buy” rating and issued a $3.00 target price on shares of Alimera Sciences in a report on Wednesday, September 5th. HC Wainwright set a $3.00 target price on shares of Alimera Sciences and gave the stock a “buy” rating in a report on Thursday, September 6th. Zacks Investment Research raised shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a report on Thursday, August 2nd. Finally, B. Riley started coverage on Alimera Sciences in a report on Friday, June 29th. They set a “buy” rating and a $2.75 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Alimera Sciences currently has a consensus rating of “Buy” and a consensus target price of $2.44.
NASDAQ ALIM traded up $0.02 during trading hours on Monday, reaching $0.98. The company’s stock had a trading volume of 41,800 shares, compared to its average volume of 151,475. The company has a quick ratio of 3.61, a current ratio of 3.85 and a debt-to-equity ratio of -0.60. Alimera Sciences has a 52 week low of $0.74 and a 52 week high of $1.42. The stock has a market capitalization of $68.64 million, a P/E ratio of -3.38 and a beta of 1.51.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ALIM. BlackRock Inc. raised its holdings in shares of Alimera Sciences by 28.5% during the second quarter. BlackRock Inc. now owns 272,248 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 60,327 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Alimera Sciences by 20.8% during the second quarter. Renaissance Technologies LLC now owns 574,000 shares of the biopharmaceutical company’s stock valued at $562,000 after buying an additional 99,000 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in shares of Alimera Sciences by 13.0% during the second quarter. Stonepine Capital Management LLC now owns 6,981,184 shares of the biopharmaceutical company’s stock valued at $6,830,000 after buying an additional 801,151 shares during the last quarter. 51.85% of the stock is currently owned by institutional investors.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Featured Story: What is intrinsic value?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.